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Abstract
Objective: Rapid developments in understanding the molecular mechanisms
underlying cognitive deficits in neurodevelopmental disorders have increased
expectations for targeted, mechanism-based treatments. However, translation
from preclinical models to human clinical trials has proven challenging. Poor
reproducibility of cognitive endpoints may provide one explanation for this
finding. We examined the suitability of cognitive outcomes for clinical trials in
children with neurofibromatosis type 1 (NF1) by examining test-retest reliability of the measures and the application of data reduction techniques to improve
reproducibility. Methods: Data were analyzed from the STARS clinical trial
(n = 146), a multi-center double-blind placebo-controlled phase II trial of
lovastatin, conducted by the NF Clinical Trials Consortium. Intra-class correlation coefficients were generated between pre- and post-performances (16-week
interval) on neuropsychological endpoints in the placebo group to determine
test-retest reliabilities. Confirmatory factor analysis was used to reduce data into
cognitive domains and account for measurement error. Results: Test-retest reliabilities were highly variable, with most endpoints demonstrating unacceptably
low reproducibility. Data reduction confirmed four distinct neuropsychological
domains: executive functioning/attention, visuospatial ability, memory, and
behavior. Test-retest reliabilities of latent factors improved to acceptable levels
for clinical trials. Applicability and utility of our model was demonstrated by
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homogeneous effect sizes in the reanalyzed efficacy data. Interpretation: These
data demonstrate that single observed endpoints are not appropriate to determine efficacy, partly accounting for the poor test-retest reliability of cognitive
outcomes in clinical trials in neurodevelopmental disorders. Recommendations
to improve reproducibility are outlined to guide future trial design.

Introduction
Advances in genetically modified animal models and
induced pluripotent stem cells have allowed detailed examination of the molecular pathways underlying cognitive
deficits in neurodevelopmental conditions. This in turn has
resulted in candidate molecular targets for therapeutic
drugs, many of which have reversed behavioral phenotypes
in animal models.1–3 Despite a significant number of clinical trials targeting cognitive deficits in patients with genetic
conditions, the vast majority have failed to translate the
encouraging findings from preclinical trials.4 The challenges of translating targeted treatments in human randomized controlled trials (RCTs) are typified by
neurofibromatosis type 1 (NF1),5–7 an autosomal dominant genetic condition associated with cognitive deficits
affecting 80% of children.8 Preclinical trials have identified
several promising therapeutic targets. Lovastatin normalizes synaptic plasticity and rescues the learning phenotype
in Nf1+/ mice by targeting RAS activation,1 while methylphenidate and L-dopa improve attention by normalizing
dopamine homeostasis in an Nf1+/ strain with bi-allelic
inactivation in neuroglial progenitor cells.9 Similarly, pharmacological blockade of Pak1 function within the amygdala rescues social deficits in Nf1+/ mice10 and the HCN
channel agonist lamotrigine rescues electrophysiological
deficits by normalizing excitability of inhibitory interneurons.11 Despite the optimism provided by these preclinical
studies, attempts at translating findings to human clinical
RCTs have been mixed (Table 1).5–7,12–16 While benefits of
methylphenidate for attention deficit/hyperactivity disorder
(ADHD) have been reported,16 and a very small study has
suggested an effect of lovastatin on learning and memory,15
three larger trials have failed to demonstrate any cognitive
benefits of statin therapy.5–7
Translation from mouse studies to effective human
clinical trials has proven difficult.4,17 Potential explanations for this include inadequacy of animal models to
recapitulate the complexity of the human disease state18,19
and the frequent use of small sample sizes,4 a common
issue of RCTs in rare genetic conditions. It is also vital
that cognitive endpoints are sensitive and reliable.20 Here,
we evaluated the suitability of various cognitive and
behavioral endpoints for clinical trials in children with
NF1 by analyzing data from the largest clinical trial for
NF1-related cognitive deficits; the NF Clinical Trials Consortium’s STAtin Randomized Study (STARS). This
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multicenter (11 sites), double-blind, randomized, placebocontrolled, parallel arm trial evaluated the efficacy of
lovastatin for cognitive and behavioral deficits in children
with NF1.5 Similar to a previous study,20 our initial aims
were to (1) determine the severity of deficits on cognitive
and behavioral outcomes at baseline and (2) examine the
test-retest reliability of outcome measures after the 16week treatment period. However, we extend this by also
(3) investigating the utility of data reduction using confirmatory factor analysis (CFA) to improve psychometric
properties of cognitive and behavioral outcomes, and (4)
re-analyzing efficacy data using CFA-derived latent
variables.

Methods
Participants
We analyzed data from the 144 children randomized in
the STARS clinical trial.5 Participants were treated with
lovastatin (n = 74, mean age 11.5 years, 58% male) or
placebo (n = 70, mean age 11.7 years, 62% male). Participants satisfied the clinical diagnostic criteria for NF1,21
were aged between 8 and 15 years at screening, and
demonstrated impaired performance on at least one primary outcome (≥1 SD below population mean). Exclusion criteria included full scale IQ < 70, symptomatic
CNS pathology, significantly impaired vision/hearing,
insufficient comprehension of English, low baseline total
cholesterol (<90 mg/dL), and medications contraindicated
on lovastatin. Children on a stable dose of stimulant
medication (one month prior to screening and for study
duration) were considered eligible.
The protocol was approved by the institutional review
board at each site. The study was performed in accordance with the Declaration of Helsinki and Good Clinical
Practice guidelines and was registered at clinicaltrials.gov
(NCT00853580). Written informed consent was obtained
from all parents/guardians before study entry.

Outcome measures
Efficacy outcomes were administered by psychologists at
baseline and after 16-weeks of treatment and have previously been described in detail.5 In brief, primary outcome
measures were the Paired Associate Learning (PAL) test
from the Cambridge Neuropsychological Automated
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Lovastatin (randomized,
parallel group, placebocontrolled, double-blind)

Simvastatin (randomized,
parallel-group, placebocontrolled, double-blind)

Simvastatin (randomized,
parallel-group, placebocontrolled, double-blind)

Methylphenidate (single
arm, open-label)

Lovastatin (single arm,
open-label, phase 1
escalation trial)

Simvastatin (randomized,
parallel group, placebocontrolled, triple-blind)

Lovastatin (randomized,
parallel group, placebocontrolled, double-blind)

6

7

12

13

14

15

Intervention (design)

5

Reference

44 (25.7, 11.6)

30 (8.1, 1.8)

12

14

FSIQ ≥ 70

12

52

Diagnosed with
comorbid ASD;
T > 60 on SRS

History of learning
disability;
FSIQ > 80

Diagnosed with
comorbid ADHD

201 (10.7, 2.2)

23 (13.0, 2.4)

No stimulant
medication

84 (11.2, 7.9-16.0)3
52

12

Nil

62 (12.4, 10.414.4)3

Treatment
weeks
16

Key selection
criteria
Impaired
performance on
primary outcome
(s); FSIQ ≥ 70

146 (11.6, 2.1)

N (Mean, SD)2

ABC; CGI-S;
Conners3; Resting
state fMRI, MRI MRS
(GABA, Glx), ADC,
ASL, peripheral
MAPK assay
BVMT-R; LNS

TEA-Ch; CVLT;
WRAML-2

TOVA

RCFT-recall;
Cancellation test;
prism adaption; MRI
ADC
CBCL-P; FSIQ

CANTAB (PAL); TEACh (Score)

Primary outcomes

Table 1. Clinical trials targeting cognitive and behavioral outcomes in children with neurofibromatosis type 1.

HVLT; Cancellation test; OA;
CBCL-P; CBCL-SR; fMRI

Nil

JLO; Grooved Pegboard; BRIEF-P;
BRIEF-SR; BASC-2-P; WASI

CBCL-P; CBCL-T

RCFT, Stroop CWI; Grooved
Pegboard; CHQ; CBCL4

CANTAB (SST, SWM, SOC); TEACh (Sky Search, Creature
Counting; Sky Search DT); CPTII; COWAT; OA; BRIEF-P; JLO;
BASC-2-P; BASC-2-SR; PedsQLP; PedsQL-SR
RCFT-copy; Stroop CWT; BD and
OA; Beery VMI; JLO

Secondary outcomes
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(Continued)

Significant improvement on
nonverbal declarative
memory, working memory,
and categorical verbal
generation; significant
improvement in internalizing
symptoms for adult patients

No significant improvement
in cognitive deficits or
behavioral problems on
simvastatin
Methylphenidate improved
cognitive and behavioral
attention; decline in
aggressive behavior and
social problems
Some improvements in verbal
and nonverbal memory
after lovastatin use, but not
in attention or vigilance
Possible effect of simvastatin
in brain regions associated
with NF1 pathophysiology
and social brain network

No significant effect of
simvastatin except for
improvement on OA

Lovastatin did not improve
visuospatial learning or
attention

Findings
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Abbreviations: ABC, Aberrant Behavior Checklist; ADC, apparent diffusion coefficient; ADHD, attention deficit/hyperactivity disorder; ASD, autism spectrum disorder; ASL, arterial spin labelling; BASC-2-P,
Behavior Assessment System for Children, Second Edition, Parent Form; BD, Wechsler Block Design; Beery-VMI, Beery Developmental Test of Visual Motor Integration; BRIEF-P; Behavior Rating Inventory of
Executive Function, Parent Report; BRIEF-SR, Behavior Rating Inventory of Executive Function, Self-Report; BVMT, Brief Visuospatial Memory Test Revised; CANTAB, Cambridge Neuropsychological Test Automated Battery; CBCL-P, Child Behavioral Checklist, Parent Report; CBCL-SR, Child Behavioral Checklist, Self-Report; CBCL-T, Child Behavioral Checklist, Teacher Report; CDI, Children’s Depression Inventory;
CDRS, Children’s Depression Rating Scale; CGI-S, Clinical Global Impression Scale; COWAT, Controlled Oral Word Association Test; CPT-II, Continuous Performance Test, Second Edition; CRS-T, Conners’ Teacher Rating Scale; CVLT, California Verbal Learning Test; CWT, Color Word Interference test; fMRI, functional magnetic resonance imaging; FSIQ, Full Scale Intelligence Quotient; GABA, gamma-aminobutyric
acid; Glx, glutamate + glutamine; JLO, Judgement of Line Orientation; LNS, Wechsler Letter Numer Sequencing; MAPK, Mitogen-activated protein kinase; NF1, neurofibromatosis type 1; OA, Wechsler Object
Assembly test; PAL, Paired Associative Learning; PedsQL-P, Pediatric Quality of Life Inventory, Parent; PedsQL-SR, Pediatric Quality of Life Inventory, Self Report; RCFT, Rey Complex Figure Test; SCRS-P, simplified Conners’ Parent Rating Scale; SOC, Stockings of Cambridge; SRS, Social Responsiveness Scale; SST, Stop Signal Task; STAI-C, State-Trait Anxiety Inventory for Children; SWM, Spatial Working Memory;
TEA-Ch, Test of Everyday Attention for Children; TOVA, Test of Variables of Attention; WRAML-2, Wide Range Assessment of Memory and Learning, Second Edition.
1
NF1 participants only.
2
Years of age.
3
Median (interquartile range).
4
Teacher and youth self-report.

Methylphenidate improved
parent rated ADHD
symptoms
CRS-T; CDRS; CDI; STAI-C
SCRS-P
9
FSIQ between 80120; attention
problems, school
problems
39 (9.3, 1.8)
Methylphenidate
(randomized, crossover,
placebo-controlled)
16

Intervention (design)
Reference

Table 1. Continued.

N (Mean, SD)2

Key selection
criteria

Treatment
weeks

Primary outcomes

Secondary outcomes
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Battery (CANTAB) assessing visuospatial learning22 and
Score from the Test of Everyday Attention for Children
(TEA-Ch) measuring sustained attention.23 Secondary
endpoints assessed attention, executive function and visuospatial skills, using Spatial Working Memory (SWM),
Stockings of Cambridge (SOC), and the Stop Signal Task
(SST) from the CANTAB, Sky Search, Sky Search DT and
Creature Counting from the TEA-Ch, the Conners’ Continuous Performance Task-II (CPT-II), Controlled Oral
Word Association Test, Judgment of Line Orientation
task, and Wechsler Object Assembly. In addition, parent
behavioral rating scales assessed ADHD symptoms with
the Conners-3, executive functions via the Behavior Rating Inventory of Executive Functions (BRIEF), internalizing behaviors on the Behavior Assessment System for
Children-II (BASC-II), and psychosocial quality of life
with the PedsQL. Participants also completed self-report
versions of the BASC-II and PedsQL.

Data analysis
Unless stated otherwise, the complete case data set was
used for all analyses. Baseline scores for all participants
were used to establish the presence of pre-treatment
cognitive and behavioral deficits. To allow direct comparisons between the various test scores, each standardized outcome was converted into a z-score such that 0
equals the reference group average with a standard deviation of 1. Differences between the NF1 group and normative reference data were tested using one-sample ttests. To determine test-retest reliability of outcome
measures, we examined associations between pre- and
post-treatment scores of the placebo group using intraclass correlations.
We then conducted a rational reduction of cognitive
and behavioral outcomes by creating a series of CFA
models to determine the best-fitting model for the different cognitive domains (executive functioning/attention, memory, visuospatial) and behavior. CFA was
chosen over exploratory factor analysis because it is a
top-down, hypothesis-driven variant of structural equation modelling that is used to examine the expected
connections between variables, treating each observed
measure as one of multiple fallible manifest indicators
of an underlying latent (i.e., unmeasured) construct.
CFA models allow for random and systematic measurement error in the observed variables and the latent constructs can be interpreted with the measurement error
taken into account. Scores were transformed prior to
CFA such that a positive score reflected superior performance. The maximum likelihood method was used, and
model assumptions examined (i.e., outliers, multivariate
normality, linearity). Power calculations indicated
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approximately 90% power to achieve statistical significance in our proposed CFA model. Several models were
tested and the best determined by the best overall fit
indices including the v2 value, normed v2 (divided by
the model degrees of freedom), Comparative Fit Index
(CFI), and the root mean square error of approximation
(RMSEA). Smaller v2 (and non-significant P-value),
normed v2(<3) and RMSEA (<0.06) values and larger
CFI (>0.9) values indicate a better fit. Standardized factor loadings of the best fitting model at baseline were
used to calculate the scores for the latent factors at
baseline and post-treatment.
As before, we determined test-retest reliability of latent
factors by examining associations between pre- and posttreatment scores of the placebo group using intra-class
correlations. We then re-examined the efficacy of lovastatin using the CFA-derived latent factors, comparing
post-treatment scores of lovastatin and placebo conditions
using analysis of covariance, adjusting for baseline scores.
These intention to treat (ITT) analyses utilized data from
participants with complete baseline data, applying multiple imputation for cases with missing 16 week data. Follow-up scores were imputed from baseline values, child
age and sex, with 20 replications. Effect sizes were calculated (Cohen’s d) to determine the magnitude of the
group comparisons such that an effect size of 0.3 is small,
0.5 medium and 0.8 large.24 All analyses were conducted
in Stata IC (version 13.1).

Results
Summary baseline results for the intention to treat population are shown in Table 2. With the exception of childreported internalizing behaviors (P = 0.459), baseline
mean scores were significantly poorer than normative reference data (all, P < 0.001), confirming the presence of
cognitive and behavioral deficits on these measures.

Test-retest reliability
Intra-class correlations between observed test values at
baseline and post-treatment (week-16) for participants
in the placebo condition are shown in Table 2. These
test-retest effects allow examination of the stability of
cognitive and behavioral outcomes of an inactive treatment within a realistic clinical trial setting. Higher correlations indicate higher stability and superior test-retest
reliability of the outcome measure between pre-post
assessments. While there are few standards for judging
the minimum acceptable value for a test-retest reliability
estimate,25 reproducibility coefficients are typically considered adequate if greater than 0.7.26 By these standards, test-retest reliability of the two primary outcomes

Cognitive Outcomes in Clinical Trials

was poor, with PAL and Score falling well below adequate levels (both, r < 0.40). Indeed, most secondary
cognitive outcomes fell below adequate levels including
widely used computerized tasks specifically designed to
assay reliable change in clinical trials settings, including
SWM and SST from the CANTAB. The SOC task in
particular was very poor (r = 0.10). More traditional
cognitive assessments tended toward higher pre-post
correlations, but only the COWAT and JLO tasks
demonstrated adequate reliabilities (both, r > 0.72). On
the whole, behavioral questionnaire ratings tended
towards higher pre-post correlations than cognitive outcomes. Parent-reported ADHD symptoms on the Conners-3 approached adequate levels, while reproducibility
of parent-reported executive behaviors on the BRIEF
was good. Parent and child-reported internalizing problems on the BASC-2 were adequate and psychosocial
quality of life was just below acceptable levels for parent
and child-report.

Confirmatory factor analysis
To reduce the number of variables and account for measurement error associated with observed variables, we
performed a series of CFAs, based on theoretical models,
using the cognitive factors of (1) executive functioning/
attention, (2) memory, (3) visuospatial ability, and (4)
general behavior on the complete-case population
(n = 104) (Table S1). The best-fitting four-factor model
is shown in Figure 1. Fit of this four-factor model was
acceptable (v2 (154) = 181.59, P = 0.06; normed
v2 = 1.18; CFI = 0.95; RMSEA = 0.041, P = 0.73), model
assumptions met, and factor loadings were significant
(all, P < 0.05). Two cognitive variables (SOC mean number of moves and CPT commission errors) were excluded
from the final model as their inclusion resulted in a poor
fit (Table S2).
Results of pre-post intra-class correlations of the four
latent cognitive and behavioral factors are shown in
Table 3. As before, only the placebo condition was analyzed, employing ITT analysis with multiple imputation
applied to those missing 16 week data. Results revealed
noteworthy increases in test-retest reliability for the four
latent variables compared to observed values reported in
Table 2. The executive functioning/attention variable
returned excellent reproducibility (r = 0.83), compared
with the test–retest reliabilities of the eight observed cognitive values loading on the latent factor (range, 0.300.82). Pre-post correlations for the visuospatial and
behavioral latent factors were also acceptable. The memory factor, consisting of PAL and SWM variables, fell
slightly below the level of reliability considered adequate
for clinical trials (r = 0.66).
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Table 2. Total sample raw and standardized summary statistics for outcomes, and test–retest results within the placebo group.
Total study population

Test-retest effects in placebo group only

Baseline

Cognitive test
PAL1
SWM1
SWM strategy1
SOC1
SST1
Score1
Sky search1
Sky search DT1
Creature counting1
CPT omission2
CPT commission2
CPT RT2
COWAT1
Object assembly3
JLO1
Behavioral questionnaires
ADHD inattentive2
ADHD hyperactive/impulsive2
BREIF BRI2
BRIEF MCI2
BRIEF GEC2
Internalizing problems – parent2
Internalizing problems – child2
PedsQL psychosocial – parent4
PedsQL psychosocial – child4

Baseline

N

Mean

SD

Z-score

143
139
139
136
135
136
137
136
137
135
135
135
137
137
135

16.1
47.1
36.7
7.9
252.2
5.9
4.7
10.0
3.9
59.7
55.6
55.0
21.8
6.8
14.9

19.4
16.2
4.4
1.3
89.8
2.2
1.9
17.2
2.2
15.2
9.1
14.2
8.8
3.1
6.2

0.7
0.9
0.7
0.5
N/A
1.7
0.7
1.7
0.8
1.0
0.6
0.5
N/A
1.0
N/A

137
137
135
135
134
133
132
133
132

64.7
63.8
57.5
63.5
62.3
54.4
50.8
64.0
65.2

13.4
14.5
12.8
11.4
11.7
12.3
9.4
17.0
16.5

1.5
1.4
0.8
1.4
1.2
0.4
0.1
1.0
1.0

16 weeks

SD

n

Mean

SD

Mean

SD

ICC

1.35
0.9
1.0
1.1
N/A
0.7
1.0
1.3
1.2
1.5
0.9
1.4
N/A
1.0
N/A

57
57
57
53
53
55
55
55
55
51
51
51
55
55
54

18.1
48.6
37.0
8.1
235.7
5.8
5.2
10.3
3.8
60.5
57.0
53.6
21.7
7.3
14.5

16.5
16.0
4.7
1.3
79.5
2.5
2.2
20.2
2.3
16.2
6.1
12.9
9.2
2.9
5.7

12.2
42.0
35.5
7.9
228.1
6.7
4.6
6.5
4.6
63.5
55.8
55.1
23.2
7.7
16.4

12.1
16.9
5.5
1.4
94.7
2.6
2.2
11.4
1.9
17.7
7.1
15.1
9.3
3.3
6.3

0.32
0.61
0.51
0.10
0.51
0.39
0.63
0.30
0.56
0.62
0.68
0.70
0.82
0.66
0.73

1.4
1.6
1.3
1.2
1.2
1.2
1.0
1.2
1.1

55
55
55
55
55
54
52
54
54

63.8
63.5
56.4
63.2
61.6
54.3
51.4
64.6
62.7

14.1
15.3
13.5
11.9
12.1
12.0
9.1
18.8
17.1

61.3
62.9
54.9
60.2
58.9
52.9
49.4
68.1
67.2

13.1
16.9
12.6
12.1
12.5
11.5
8.6
17.1
17.7

0.65
0.68
0.79
0.78
0.80
0.72
0.78
0.65
0.69

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; BRI, Behavioral Regulation Index; BRIEF, Behavior Rating Inventory of Executive Function; COWAT, Controlled Oral Word Association Test; CPT, Continuous Performance Test, Second Edition; DT, Divided Attention; GEC, Global
Executive Composite; ICC, Intraclass correlation coefficient; M, Mean; MCI, Metacognition Index; PAL, Paired Associated Learning; RT, Reaction
Time; SOC, Stockings of Cambridge; SST, Stop Signal Task; SWM, Spatial Working Memory; N/A, Normative reference data not available.
1
Raw score.
2
T score.
3
Age scaled score.
4
Summary score.

Having established superior psychometric properties of
the CFA-derived latent variables, efficacy data from the
STARS clinical trial were reanalyzed using the latent variables (Table 4). Again, this ITT analysis incorporated
multiple imputed 16 week data where missing. While the
analysis revealed no significant effect of lovastatin on any
of the latent variables (all, P > 0.17), the consistency of
effect sizes for the latent variables was considerably
increased compared to those reported for the observed
test scores. For example, lovastatin demonstrated a similar
positive but non-significant effect on all three CFAderived cognitive variables (d range; 0.24–0.26). In comparison, the observed test scores revealed noticeably more
variation (d range; 0.23 to 0.36).5
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Discussion
The selection of reliable outcomes that are sensitive to
change is critical to the interpretation of any clinical trial,
and is a particularly important issue for cognitive studies.
Unreliable measures adversely affect the ability to detect
positive responses to treatments and may explain the
translational failure of mechanism-based clinical trials
across a wide number of genetic conditions.4 Here we
present a detailed and methodical reexamination of the
outcome data from STARS to advance the design of
future cognitive clinical trials.
First, consistent with previously published data,8,20 we
demonstrated broad-ranging cognitive and behavioral
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Figure 1. Data reduction for neuropsychological measures conducted
using confirmatory factor analysis. The conceptual model shows how
we hypothesized our observed variables (parallelogram) related to the
four latent cognitive constructs (ellipse). For ease of presentation the
diagram shows standardized factor loadings but does not contain
error terms, cross loadings, or correlations between latent factors.
ADHD, attention-deficit/hyperactivity disorder; BRI, Behavioral
Regulation Index; BRIEF, Behavior Rating Inventory of Executive
Function; COWAT, Controlled Oral Word Association Test; CPT,
Continuous Performance Test, Second Edition; DT, Divided Attention;
GEC, Global Executive Composite; ICC, Intraclass correlation
coefficient; M, Mean; MCI, Metacognition Index; PAL, Paired
Associated Learning; RT, Reaction Time; SOC, Stockings of
Cambridge; SST, Stop Signal Task; SWM, Spatial Working Memory.

deficits in participants with NF1. All baseline cognitive
outcomes were significantly below population reference
data with particularly large deficits seen on sustained and
divided attention measures from the TEA-Ch, confirming
attention as a key cognitive deficit in NF1.27 At the
behavioral level, inattentive and hyperactive ADHD symptoms and executive behaviors were rated as the most significant problem areas. Consistent with previous
evidence,20 internalizing problems were less affected in
our cohort.
Second, this study revealed poor reliability of commonly
used cognitive outcomes in a real-life clinical trial setting.
This was particularly striking for the CANTAB tasks, which
all demonstrated test–retest reliabilities below acceptable
levels, and in some cases, reproducibility was very poor.
The variability noted across most cognitive tests was sufficiently substantial to compromise outcome stability, limiting the sensitivity of observed values to detect true change
in this population. Importantly, reliabilities were considerably lower than published reliabilities in normative samples. As such, reliabilities of TEA-Ch subtests were
markedly lower (range, 0.30–0.63) than those reported in a
normative sample (range, 0.64–0.90).23 While direct comparison of individual CANTAB tasks is more difficult, data
from adult populations suggest higher reliabilities in neurotypical samples (range, 0.60–0.68) compared with our
clinical trial (range, 0.10–0.61).28
These results raise important questions about the
source of the poor reproducibility. One possible account
is that executive tests of frontal lobe functioning are particularly sensitive to practice effects and are only valid
when they are novel, since performance on these evaluations can rapidly improve as soon as an optimal strategy
is discovered (practice effect), but will improve less if no
strategy is found.28,29 However, there is no clear explanation as to why strategy-driven practice effects would be
differentially affected in children with NF1. Poor reliability was also observed on non-executive tests, including

ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

2561

Cognitive Outcomes in Clinical Trials

J. M. Payne et al.

Table 3. Test–retest effects of latent cognitive and behavioral domains from the intention to treat placebo group1.
Total complete case
population

Test-retest effects, placebo group only

Baseline

Latent variable
EF/attention
Visuospatial
Memory
Behavior

Baseline

M

SD

n

M

0.01
0.04
0.02
0.03

0.23
0.38
0.48
0.51

50
50
50
50

0.02
0.02
0.03
0.04

16 weeks
SD

M

0.25
0.37
0.45
0.53

0.04
0.08
0.07
0.02

SD

ICC

0.24
0.41
0.39
0.53

0.83
0.78
0.66
0.84

Abbreviations: EF, Executive functioning; ICC, Intraclass correlation coefficient; M, Mean; SD, Standard deviation.
1
Multiple imputation applied to all placebo cases with baseline data (20 replications).

Table 4. Between group comparisons at 16 week using latent cognitive and behavioral domains from the intention to treat population.
Control
Week 0
Outcome

n

M

Latent variable
EF/attention
Visuospatial
Memory
Behavior

50
50
50
50

0.02
0.02
0.03
0.04

SD

0.25
0.37
0.45
0.53

Lovastatin
Week 16
M

0.03
0.08
0.07
0.03

Week 0

Week 16

SD

n

M

SD

M

SD

b

0.24
0.40
0.40
0.54

54
54
54
54

0.01
0.04
0.03
0.00

0.19
0.39
0.50
0.47

0.03
0.04
0.07
0.00

0.21
0.41
0.55
0.53

0.04
0.07
0.11
0.05

95%CI

0.02
0.04
0.05
0.09

to
to
to
to

0.09
0.17
0.27
0.19

P

d

0.174
0.208
0.184
0.474

0.26
0.24
0.26
0.14

95%CI

0.13
0.14
0.12
0.24

to
to
to
to

0.65
0.63
0.65
0.53

Abbreviations: EF, Executive functioning; M, Mean; SD, Standard deviation; d, Cohen’s d.

our two primary outcomes, arguing against a strategy
effect. A further explanation for poor reproducibility in
this study is that the characteristic attention deficits in
NF1 result in variable performances and low stability
across all cognitive measures.27 In this instance, high variation in attention, impulse control, and perhaps motivation in clinical populations such as NF1 may critically
reduce the reliability and validity of observed cognitive
test scores such that they are unable to reliably quantify
the cognitive domain the test is purported to assess.
Third, we found that a theory-based reduction of our
cognitive and behavioral outcomes using CFA considerably improved the reproducibility of our endpoints. CFA
in hypothesis-driven cognitive trials offers several advantages. In measurement theory, each observed cognitive
test outcome reflects the underlying “true” score of the
unmeasured latent construct with measurement error.
CFA allows the loading of multiple observed values onto
an underlying latent construct while modeling measurement error. As such, inferences about latent constructs
can be interpreted as if measurement error was
removed.30 Once error was accounted for in our model,
reproducibility of the executive functioning/attention,
visuospatial, and behavioral latent factors exceeded
acceptable
levels
for
clinical
trials.
Critically,
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reproducibility of these latent factors improved despite
the background of unreliable observed data.
Fourth, applicability and utility of our model was
demonstrated by the consistent range of effect sizes across
the reanalyzed efficacy data. Analysis of the three cognitive latent variables suggested small, uniform, but nonsignificant effects of lovastatin across all cognitive
domains and that there is no clinical benefit of lovastatin.
However, the consistency of treatment effects was considerably increased compared to previously reported effects
using observed cognitive test scores,5 demonstrating the
advantages of data reduction and error modelling with
CFA. The uniformity of treatment effects favoring lovastatin raise the possibility that statin therapy produced
cognitive effects somewhat analogous to the results
reported in preclinical trials,1 but that the effect size was
too small to yield statistical and clinical significance.
While we do not recommend lovastatin as a treatment
for cognitive deficits based on these results, our analyses
suggest that proof-of-concept trials in genetic conditions
such as NF1 should not be considered futile, and that
variables, such as outcome measures utilized, sample size,
as well as the dose, length and age of treatment, need to
be carefully considered in pre-trial therapeutic analyses.
Other novel surrogate outcome measures, such as
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biomarker assessments and functional neuroimaging,31
may prove more sensitive to change than cognitive tests.
Interestingly, the consistent effects across all cognitive
domains also suggest that any benefits of targeted treatments in NF1 may not necessarily be confined to cognitive tasks attempting to replicate murine behavioral
paradigms, or indeed to a particular cognitive domain.
Rather, cognitive domains and outcomes selected should
focus on areas of high clinical relevance to the NF1 population.
There are several critical lessons from this study which
should be instructive to guide future cognitive clinical trials. The inherent variability on cognitive testing in clinical
cohorts such as NF1 suggest that a single observed endpoint to estimate a cognitive ability is likely not appropriate. Poor reliability reduces statistical power, which calls
for a substantial increase in sample size (not cost effective
or feasible for rarer disorders), or an unacceptably high
increase in the risk of false-positive or negative results,
which may have resulted in false-positive findings in previous trials.5,6,15 Before developing a clinical trial protocol, we strongly recommend piloting potential cognitive
outcomes at multiple time points in an untreated clinical
group to provide (1) base rates of deficits, (2) reproducibility of the specific cognitive endpoints and (3) valuable data on reliability to inform sample size calculations
for clinical trials. Given specific cognitive tests are unlikely to return adequate reliability using observed test
scores, investigators should consider applying targeted
batteries of tasks and data reduction techniques, such as
CFA, to decrease the number of comparisons made and
reduce measurement error, thereby maximizing the reproducibility of cognitive outcomes.
It is also important to reflect on these recommendations within the context of the US Food and Drug
Administration (FDA) Regulatory Standards used for
approving new drugs. While specific guidance regarding
observed versus latent performance outcome variables are
not provided, the FDA stipulates that the study protocol
and report of results should explain the variables measured, the methods of observation, and the criteria used
to assess response. Importantly, the assessment methods
should also be reliable.32 Thus in order to retain the
integrity of a priori reporting of methodology with the
study protocol and on clinical trial registries, it is essential
that the planned treatment of cognitive data be documented before trial commencement and that the choice
of cognitive tasks, as well as their theoretical grouping, is
guided by current conceptual models. It is also important
that cognitive endpoints are sensitive to intervention. To
this end, multifactorial scores that fully or partially rely
on crystalized abilities, such as full scale IQ, are not recommended as cognitive endpoints for shorter-term trials
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(e.g., 16 weeks),33 as the abilities they measure (learned
knowledge and facts based on experience) are likely to
require >12 months to demonstrate change.
When interpreting the current results, it is important
to consider that test-retest reliability was assessed within a
placebo condition. While it is possible that a genuine placebo effect influenced reliability coefficients,34 our analyses retain the distinct advantages of examining data from
a realistic clinical trial setting using a blinded, randomized
sample. Importantly however, we have demonstrated here
that despite any potential placebo effects, test-retest reliability of cognitive outcomes can be considerably improved
through the application of careful, theory-driven data
reduction methods.
In conclusion, this study highlights the importance of
reliable cognitive endpoints in clinical trials. To improve
translation from preclinical studies, future clinical trials
will need to adopt methodologies that overcome the limitations of cognitive assessment. Although the results for
this study are specific for NF1, the methods and recommendations discussed are likely to be relevant for other
neurodevelopmental disorders, including autism and
ADHD.
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